In September 2024, the FTC filed suit against the three major PBM companies CVS Caremark, Express Scripts, and OptumRx along with their affiliated group purchasing organizations, alleging that their practices had artificially inflated insulin prices by favoring high-list-price insulins on formulary to maximize rebate revenue
Though theyre a useful tool to convey the risks of potentially dangerous medications, researchers say that the FDAs process of adding or removing black box warnings lacks transparency
Patients should always follow the specific Instructions for Use provided with their medication rather than modifying the technique on their own
Cordero, P., Gomez-Uriz, A
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown remarkable results in clinical trials